Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Keith J. Chappell, Kate Guilfoyle et al.|Clinical & Translational Immunology|2021Cited by 62
Molecular clamp stabilised Spike protein for protection against SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|Unknown|2020Cited by 15
Rapid Application of the Molecular Clamp Platform for SARS-CoV-2Daniel Watterson, Keith J. Chappell, Danushka K. Wijesundara et al.|SSRN Electronic Journal|2020Cited by 1
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind, Active Comparator, Phase I TrialKeith J. Chappell, Daniel Watterson, Francesca L. Mordant et al.|The Journal of Infectious Diseases|2025Cited by 1